No Dispensaries in Irvine? No Problem. Here’s the truth: Irvine, California currently prohibits cannabis dispensaries from operating within city limits. So if you’ve been Googling “dispensary in Irvine” or “Irvine dispensary,” you won’t find a storefront legally operating in the city. But that doesn’t mean you’re out of options. Premier 1 Cannabis is a licensed
Florida is once again considering legalizing recreational marijuana, with proponents aiming for the November 2026 ballot after a previous attempt for 2024 faced Supreme Court rejection. This new initiative seeks to overcome past legal hurdles, potentially bringing significant economic and social changes to the Sunshine State. If successful, it could introduce a thriving adult-use cannabis market, reduce justice system burdens, and enhance personal freedoms for Floridians.
Remember all the buzz around Florida’s recreational cannabis ballot initiative for 2024? While that particular push didn’t quite make it over the finish line in the way many hoped, don’t pack away your “legalize it” signs just yet. It seems the Sunshine State is gearing up for another shot at adult-use cannabis, this time with a potential eye on the November 2026 ballot. Yes, you heard that right – recreational marijuana could be returning to Florida’s political arena, and frankly, it’s got us pretty excited.It’s like that familiar feeling of waiting for your favorite band to announce a new tour. You know it’s coming, but the exact date and venue are always a bit of a suspense. For cannabis advocates in Florida, the “venue” is the ballot box, and the “tour date” might just be 2026.
Déjà Vu All Over Again? The 2024 Attempt
Let’s quickly rewind to understand why this 2026 news is such a big deal. For the 2024 election cycle, a significant effort was made to get a recreational cannabis amendment on the ballot. Groups worked tirelessly to gather the necessary signatures, and they succeeded! However, the state Supreme Court ultimately ruled against the specific language of the proposed amendment, deeming it potentially misleading or not clear enough about its impact. It was a real gut punch for many, highlighting just how high the legal hurdles are in Florida when it comes to cannabis reform.It wasn’t a total loss, though. The sheer volume of support and signatures gathered showed there’s a massive appetite among Floridians for legal recreational marijuana. That public desire hasn’t gone anywhere; if anything, it’s only grown stronger.
Enter 2026: A New Hope for Florida Cannabis.
So, what’s different this time? While details are still emerging, the key takeaway is that proponents aren’t giving up. This new initiative aims to learn from the challenges of the 2024 attempt, carefully crafting an amendment that can withstand the intense scrutiny of the state Supreme Court. If the new language qualifies and passes legal review, we could see a powerful movement to get it onto the November 2026 ballot. Why 2026? Well, these things take time. Gathering hundreds of thousands of valid signatures across the state, navigating complex legal challenges, and building public awareness isn’t an overnight task. A 2026 timeline allows for more meticulous planning and a stronger, more resilient campaign. Think of it as refining the recipe after the first batch didn’t quite rise as expected – you tweak the ingredients, adjust the temperature, and try again, hoping for a perfect bake.
The Potential Impact of Legal Weed in the Sunshine State
If Florida does finally legalize adult-use cannabis, what could it mean for the state? The implications are huge, spanning economic, social, and even cultural shifts.* Economic Boom: We’re talking about a multi-billion dollar industry. Think new businesses, thousands of jobs from cultivation to retail, and significant tax revenue that could fund public services. States like Colorado and California have seen their coffers swell with cannabis taxes – why not Florida? Reduced Burden on the Justice System: Legalizing recreational marijuana means fewer arrests for minor cannabis offenses, allowing law enforcement to focus on more serious crimes. It also offers a chance to address past injustices related to cannabis prohibition. Tourism Appeal: Florida is already a global tourist magnet. Imagine adding regulated adult-use cannabis to the mix. It could draw even more visitors looking for a safe, legal, and enjoyable experience. Personal Freedom: For many Floridians, it’s about personal liberty and the right to responsibly consume a substance that’s widely accepted and used across the nation.Of course, the medical marijuana program in Florida is already robust and serves hundreds of thousands of patients. Legalizing recreational cannabis would expand access and normalize the plant even further, potentially reducing stigma for all users.
What’s Next? Keeping an Eye on the Ballot
While it’s exciting to imagine recreational marijuana in Florida by 2026, it’s crucial to remember that this is still a developing story with significant hurdles ahead. The process will involve extensive signature gathering and, crucially, another review by the Florida Supreme Court. This court approval is the make-or-break moment. So, stay tuned! If you’re a Floridian who believes in cannabis reform, keeping an eye on these developments and understanding the process will be key. This isn’t just about getting high; it’s about economic opportunity, personal freedom, and modernizing state policy. The green dream for Florida might just be closer than ever.
One of my favorite office-gear gifts is a small sign that sits on my desk. It simply says, “Shit. I forgot to create a personal brand.”
All joking aside, a personal brand is a must for anyone in business today, particularly for those of us in the cannabis space. Given our industry’s competitive nature, its breakneck evolution over the past decade, and the anticipation of what rescheduling could mean for all of us in the next one, we are all thinking about how we can appeal to a wider population of consumers and the bigger potential markets we can create.
In an industry still navigating the shift from legacy to legal, a personal brand acts as a bridge of trust for skeptical investors and new consumers alike.
Personal brands are nothing new. In business-talk circles, the idea has been around for more than forty years. At its core, establishing a personal brand means building your reputation and explaining your value. We’ve been doing that in our resumes for years.
What is new is intention and how you apply your personal brand to today’s hyper-connected social media age. And if you’re not intentionally putting your personal brand to use, someone is likely already doing it for you. So, take the reins yourself.
As I advise my firm’s clients, “Tell your own story — because if you don’t, someone else will.”
A personal brand is the consistent, authentic reputation you build by clearly communicating your value and showing it through your actions and visibility. Your personal brand is rooted in who you are. At the risk of repeating an overused term, it’s who you authentically are.
You’ve seen people who are authentic. They break through the noise and grab attention. Think Gary Vaynerchuk, an entrepreneur, author, and motivational speaker with 11.2 million Instagram followers. Or Carolyn Davis, known online as MississippiKween, who turned a viral breakfast pizza video into a cookbook and kitchen product empire with business collaborations and 2 million Tiktok followers. While their niches differ, their core success is identical: They’ve replaced corporate artifice with human connection. They are successful because they are comfortable in how they communicate their ideas. That is who they are. There is no artifice. No performance.
Certainly, those are extreme examples. And frankly, I’d love to have their audiences. But their success follows a key guiding principle: authenticity as brand.
How do you create your personal brand to make sure your business colleagues see the authentic you?
We’re all on social media. But how well are you using your social media? Are you posting regularly to LinkedIn, Instagram, or TikTok? Are you bolstering your website with links back and forth to your social media pages?
And remember: Social media is about being social. So go out there and amplify your brand on social media. Share any publicity you receive. Use LinkedIn or Substack to share information about your awards, your accolades, your milestones. By consistently sharing these subtly, quietly, and strongly, you’ll position yourself as a thought leader.
It’s also important to make sure you engage with people in the real world, telling your story and sharing your value face-to-face. Yes, that means networking. That means attending and participating in conferences. That means “getting out there.”
To be sure, your personal brand will evolve over time as your personal goals develop and as the cannabis industry grows and changes. Being flexible and re-evaluating your brand should always be part of the plan.
A personal brand is your reputation: how people describe you, what they trust you for, and the value they associate with your name.
Because the industry is competitive and fast-changing, a strong personal brand helps you stand out, build credibility, and expand opportunities as markets evolve.
Start with clarity: define what you do best, what you enjoy, what you want to be known for, and the value you bring. Then craft a simple story that connects those points.
Use the platforms where your professional audience already pays attention — often LinkedIn first, then Instagram or TikTok depending on your role and goals.
Consistency matters more than volume. Choose a cadence you can sustain (for example, 1–2 quality posts per week) and engage with others regularly.
Focus on usefulness and proof: share insights, lessons learned, milestones, and earned recognition in a calm, factual tone — then amplify others, too.
No. Your brand should evolve as your goals change and the industry changes—revisit it periodically and adjust intentionally.
Kim Prince is founder and chief executive officer at Proven Media, a results-oriented agency serving business- and consumer-facing companies throughout North America. She brings more than twenty years of corporate marketing experience and leverages her background in corporate messaging strategies, public relations, and strategic planning to help position corporations, brands, and C-level executives for growth.
The global cannabis industry barely had time to catch its breath over the Christmas break, following several seismic developments at the tail end of the year.
The rescheduling news alone triggered a dramatic market rally, with stocks like Tilray Brands surging 125% and Curaleaf Holdings jumping 212%.
Cannabis-focused REITs have also drawn renewed attention, with analysts highlighting companies like Innovative Industrial Properties trading at 8x FFO with mid-teens dividend yields, and NewLake Capital Partners positioned for potential NASDAQ uplisting once the SAFER Banking Act passes.
That frantic pace has carried straight into 2026, with the opening weeks delivering a flurry of major transactions and legal disputes as companies scramble to adapt to a ‘maturing market’.
High Tide’s recently acquired German subsidiary, Remexian Pharma, has secured dual court victories against competitors in the thriving German medical cannabis market.
In September, we reported on an emerging legal dispute between Remexian and competitor Vayamed that erupted just hours after High Tide closed its €27.2m acquisition of a 51% stake in the German distributor.
Vayamed, through international law firm Hogan Lovells, accused Remexian of violating Germany’s Medicines Act by marketing multiple cannabis cultivars under single authorisation numbers, a practice Vayamed argued required separate approvals for each strain.
The timing of the challenge raised questions among industry insiders, with High Tide CEO Raj Grover dismissing it as a coordinated attack designed to undermine the transaction.
He alleged that Remexian’s valuation was notably lower multiples (roughly 1x sales and 3.6x EBITDA) than many German cannabis assets had previously commanded, thus causing concern among these firms that their valuations would suffer based on this established precedent.
StratCann reported that on January 14, 2026, the Berlin Court of Appeal partially granted an injunction against Vayamed, part of German medical cannabis firm Sanity Group.
Business of Cannabis has subsequently obtained the full 31-page ruling from the Berlin Court of Appeal (Kammergericht Berlin), which states that Vayamed is prohibited from distributing five specific statements from its August 26, 2025 cease-and-desist letter to third parties, including competitors and journalists.
The prohibited statements relate to Vayamed’s allegations that Remexian violated Germany’s Medicines Act (AMG) by marketing multiple cannabis cultivars under single authorisation numbers.
In a significant finding, the court classified Vayamed’s statements as ‘Meinungsäußerungen’ (expressions of opinion) rather than factual claims subject to Germany’s strict defamation standards. The court found these statements represented ‘legal assessments’ and ‘value judgments’ about regulatory requirements rather than provable facts.
However, the court ruled that distributing these opinions to third parties before even serving the cease-and-desist letter to Remexian itself constituted unlawful disparagement under Section 4 Number 1 of Germany’s Unfair Competition Act (UWG).
However, the ruling explicitly avoids determining whether Remexian’s actual business practices comply with German pharmaceutical law. The court noted that Vayamed’s cease-and-desist letter did not make clear ‘from which concrete circumstances’ the alleged lack of proper authorisation was derived.
The court also rejected Remexian’s claims against two statements made by Sanity Group CEO Finn Hänsel in a StratCann article, finding these either too vague to constitute disparagement or adequately balanced by Remexian’s own quoted response in the same article.
Omar Khan, Chief Communications and Public Affairs Officer at High Tide, told Business of Cannabis: “The Berlin Court of Appeal took a cautious approach in its ruling and avoided making a final call on whether the disputed statements were facts or opinions. Instead, it found that the statements appeared to be opinions and were defamatory and therefore not permitted.
“Importantly, the Court said the allegations were made on an unclear factual basis — meaning they were not backed by evidence. The warning letter failed to clearly explain what licenses Remexian holds or why Vayamed believed those licenses did not allow the marketing of different strains.
“In a related case involving Demecan, the Berlin District Court went further and found that the underlying allegations were factually false, not just vague or unproven. We believe that the ruling should also be taken into account.
“While cease-and-desist orders do not always list corrective steps in detail, they require false statements to be withdrawn and corrected. This includes removing published claims and taking steps to ensure third parties do not continue to repeat them.”
Vayamed was ordered to bear 80% of the appeal proceeding costs, with Remexian bearing 20%.
An earlier ruling from Berlin Regional Court in October 2025 found that Remexian had credibly demonstrated its products were authorised, noting that authorisations referred to cannabis flowers with specific THC and CBD content rather than specific cultivars. However, that ruling also does not constitute a final determination of the regulatory question.
In a separate legal case, Remexian also went on the offensive against Germany’s booming telemedicine platforms
While defending itself from competitor attacks, Remexian has also gone on the offensive against telemedicine platforms it accuses of unlawful advertising and sales practices.
In early December, the Hamburg Regional Court granted Remexian a preliminary injunction against Dr Ansay Ltd.
The 146-page ruling identified nine specific violations of Germany’s Medicines Advertising Act, including presenting cannabis products in an online shop format, advertising THC edibles in newsletters, and openly selling sick notes.
“Our motivation stems from the current political climate,” Stefan Adomeit, Remexian’s co-managing director, told German media. “As a wholesaler of medical cannabis, it is important to us that telemedicine is offered within the existing rules.”
The injunction prohibits the platform from advertising prescription-only medicines to the general public, maintaining marketplace-style product pages that highlight psychoactive effects, and brokering prescriptions through online questionnaires rather than telephone or video consultations.
However, enforcement is proving difficult. Because Dr Ansay is registered in Malta, the Hamburg court must serve the injunction there, a process that has delayed action.
Two of Australia’s largest medicinal cannabis companies have agreed to merge, creating what they claim will be one of the largest pure-play cannabis businesses globally with significant European growth potential.
Little Green Pharma (ASX: LGP) announced on January 14 that it will acquire 100% of Cannatrek in an all-stock transaction, though Cannatrek shareholders will end up controlling the majority of the combined company
Under the agreed exchange ratios, Cannatrek shareholders will hold approximately 60.5% of the combined group at completion, with existing LGP shareholders retaining 39.5%. The contingent value shares could increase Cannatrek’s ownership by up to an additional 8% based on future performance milestones.
Based on 2025 financial year results, the pro forma combined group would have generated A$112 million in revenue, A$13 million in adjusted EBITDA, and held A$15 million in cash.
The merger combines LGP’s European manufacturing footprint, including Denmark’s largest medicinal cannabis production facility, with Cannatrek’s Australian market dominance and what both companies describe as ‘Australia’s highest-selling medicinal cannabis flower by a significant margin.’
LGP Managing Director Paul Long said the deal was a response to industry consolidation pressures: “As the current Australian and global cannabis markets drive towards consolidation and greater maturity, this transaction will ensure the Combined Group emerges as one of the largest and most vertically integrated medicinal cannabis businesses globally.”
The combined entity will operate GMP-certified manufacturing facilities in both Australia and Denmark, with significant latent capacity available to support growth. Cannatrek currently operates one of Australia’s largest medicinal cannabis manufacturing facilities and employs approximately 80 staff across its operations, including proprietary B2B pharmacy Greenship and telehealth clinic MyEden.
Both boards unanimously recommend the transaction, with the Cannatrek board representing 22% of shares and the LGP board representing 13.1% of shares committing to vote in favour, subject to independent expert approval and absence of superior proposals.
Berlin-based Medios AG, a publicly traded specialty pharmaceuticals provider, has entered the medical cannabis market by securing exclusive distribution rights for Bedrocan products across Germany, Spain, Belgium, Italy, and Austria.
The deal announced January 19 initially covers medicinal cannabis from Bedrocan’s EU-GMP certified production facility in Denmark, with expansion to other Bedrocan facilities planned from January 2027. Bedrocan is a leading international manufacturer of pharmaceutical-grade medicinal cannabis with over 20 years of specialisation in cannabis as an active pharmaceutical ingredient.
Medios will focus specifically on the reimbursable segment of medical cannabis rather than the self-pay market, positioning the deal as strategic protection against potential regulatory changes affecting recreational use. The partnership will initially concentrate on the German market before gradual expansion across other European territories over the next two years.
Germany-based Cannaflos will support Medios as a distribution partner.
The post From Courtrooms to Boardrooms: 2026 Consolidation Accelerates as Cannabis Companies Merge, Battle and Partner appeared first on Business of Cannabis.
As Europe’s cannabis market accelerates, one thing is becoming increasingly clear: Germany is no longer just a policy experiment. It’s the engine.
From medical cannabis growth to the rollout of social clubs, seed and clone commerce, and pilot programs for regulated adult-use supply chains, Germany is now shaping the pace and structure of Europe’s cannabis economy. And this April, that momentum converges at International Cannabis Business Conference (ICBC) Berlin 2026, returning April 13–15 at the Estrel Berlin Hotel.
High Times is a media partner of ICBC Berlin 2026.
ICBC Berlin has established itself as Europe’s largest cannabis-focused B2B event, drawing operators, investors, policymakers, suppliers, and infrastructure providers from across the continent and beyond. The conference consistently attracts:
But the relevance of the 2026 edition goes beyond scale.
Germany’s cannabis market is entering a decisive phase. Medical patient enrollment has surged following the removal of cannabis from the country’s Narcotics List. Commercial trade in seeds and clones is now legal nationwide. Member-based social cannabis clubs are expected to launch soon. Pilot commerce models are advancing. And further regulatory clarity around CBD is anticipated this year.
For companies operating anywhere in the European cannabis ecosystem — or looking to enter it — Germany has become unavoidable.
ICBC Berlin is built around participation, not passive attendance. The event brings together licensed pharmacies, social clubs, grow shops, manufacturers, genetics providers, technology firms, compliance specialists, and international brands looking to establish or expand their European footprint.
To facilitate real business, ICBC offers free passes to select buyer categories, including German social clubs, cannabis pharmacies, and European grow shops — ensuring that exhibitors aren’t just networking, but meeting decision-makers.
What might take years of outreach and travel can often be accomplished in days under one roof.
With interest building ahead of April, ICBC has announced that ticket prices will increase by €150 on January 28. For operators planning to attend, exhibit, or sponsor, the current pricing window represents an opportunity to secure access before costs rise.
While the full 2026 program has not yet been announced, ICBC Berlin’s value has historically rested less on hype and more on proximity — proximity to capital, to partners, to regulators, and to the people actively building Europe’s cannabis infrastructure.
As Germany continues to define the next phase of legalization and commerce, ICBC Berlin remains one of the few places where the continent’s cannabis business actually comes together.
High Times is a media partner of ICBC Berlin 2026.
<p>The post Europe’s Cannabis Industry Is Growing Fast. ICBC Berlin Is Where It Connects first appeared on High Times.</p>
NORML worked with union members for nearly two years to assist them in securing the revisions.
The post Maryland: Howard County Firefighters No Longer Face Sanctions for Off-Hours Use of Medical Cannabis appeared first on NORML.
We’re living in a golden era for cannabis enthusiasts. There have never been more ways to enjoy the plant, with innovative products and delivery systems hitting the market all the time. It all started with joints being passed around between friends, but over the last decade we’ve witnessed the rise of extracts, concentrates, and oils
Mango Express produces vibrant buds that showcase the best qualities of its powerhouse lineage. The aroma is a complex treat, hitting you with a sweet scent of ripe mango and pineapple. As you exhale, you will notice a smooth finish of floral notes mixed with a punch of classic diesel. The effects start quickly with a wave of euphoria that clears the mind and boosts your mood. Over time, a gentle relaxation spreads through the body, easing stress without making you feel sleepy or unmotivated. This balance makes it ideal for social gatherings or if you want to indulge in artistic hobbies.
The post Mango Express Strain Feminized Seeds appeared first on Crop King Seeds.
Running a cannabis business takes vision, grit, and a few key people who make it all happen. But what happens if one of those people, your master grower, CFO, or co-founder, suddenly can’t be there? For many cannabis companies, that kind of loss can be devastating. That’s where key man insurance comes in. What Is…
The post Protecting Your Cannabis Business with Key Man Insurance. first appeared on .
